137 related articles for article (PubMed ID: 26232698)
1. Disease dynamics in patients with acute myeloid leukemia: new biomarkers.
Tzoran I; Rebibo-Sabbah A; Brenner B; Aharon A
Exp Hematol; 2015 Nov; 43(11):936-43. PubMed ID: 26232698
[TBL] [Abstract][Full Text] [Related]
2. PO-46 - Influence of extracellular vesicles derived from AML patients on stem cells and their microenvironment.
Tzoran I; Rebibo-Sabbah A; Brenner B; Aharon A
Thromb Res; 2016 Apr; 140 Suppl 1():S193. PubMed ID: 27161733
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.
Caivano A; La Rocca F; Simeon V; Girasole M; Dinarelli S; Laurenzana I; De Stradis A; De Luca L; Trino S; Traficante A; D'Arena G; Mansueto G; Villani O; Pietrantuono G; Laurenti L; Del Vecchio L; Musto P
Cell Oncol (Dordr); 2017 Feb; 40(1):97-103. PubMed ID: 27761889
[TBL] [Abstract][Full Text] [Related]
4. High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia.
Fang Z; Wang X; Wu J; Xiao R; Liu J
Cancer Biomark; 2020; 27(1):1-9. PubMed ID: 31594209
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.
Aref S; Salama O; Al-Tonbary Y; Mansour A
Hematology; 2004 Apr; 9(2):113-21. PubMed ID: 15203866
[TBL] [Abstract][Full Text] [Related]
6. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.
Gheldof D; Haguet H; Dogné JM; Bouvy C; Graux C; George F; Sonet A; Chatelain C; Chatelain B; Mullier F
J Thromb Thrombolysis; 2017 Feb; 43(2):224-232. PubMed ID: 28074413
[TBL] [Abstract][Full Text] [Related]
7. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
8. Effects of Low- and High-Dose Chemotherapy Agents on Thrombogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines.
Aharon A; Sabbah AR; Issman L; Berkovich H; Copty R; Talmon Y; Brenner B
Thromb Haemost; 2018 Mar; 118(3):480-489. PubMed ID: 29490409
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function.
Aharon A; Sabbah A; Ben-Shaul S; Berkovich H; Loven D; Brenner B; Bar-Sela G
Oncotarget; 2017 Sep; 8(38):63265-63280. PubMed ID: 28968987
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients.
Wierzbowska A; Robak T; Krawczyńska A; Pluta A; Wrzesień-Kuś A; Cebula B; Robak E; Smolewski P
Ann Hematol; 2008 Feb; 87(2):97-106. PubMed ID: 17849117
[TBL] [Abstract][Full Text] [Related]
12. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles.
Minciacchi VR; You S; Spinelli C; Morley S; Zandian M; Aspuria PJ; Cavallini L; Ciardiello C; Reis Sobreiro M; Morello M; Kharmate G; Jang SC; Kim DK; Hosseini-Beheshti E; Tomlinson Guns E; Gleave M; Gho YS; Mathivanan S; Yang W; Freeman MR; Di Vizio D
Oncotarget; 2015 May; 6(13):11327-41. PubMed ID: 25857301
[TBL] [Abstract][Full Text] [Related]
13. Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML.
Koenecke C; Kümpers P; Lukasz A; Dammann E; Verhagen W; Göhring G; Buchholz S; Krauter J; Eder M; Schlegelberger B; Ganser A
Ann Hematol; 2010 May; 89(5):459-67. PubMed ID: 20054548
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays.
Noubouossie DC; Lê PQ; Rozen L; Debaugnies F; Ferster A; Demulder A
Thromb Res; 2012 Aug; 130(2):259-64. PubMed ID: 22079446
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics.
Kontopoulou E; Strachan S; Reinhardt K; Kunz F; Walter C; Walkenfort B; Jastrow H; Hasenberg M; Giebel B; von Neuhoff N; Reinhardt D; Thakur BK
Ann Hematol; 2020 Mar; 99(3):459-475. PubMed ID: 31932899
[TBL] [Abstract][Full Text] [Related]
16. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis.
Levin C; Koren A; Rebibo-Sabbah A; Koifman N; Brenner B; Aharon A
Front Physiol; 2018; 9():1214. PubMed ID: 30214417
[TBL] [Abstract][Full Text] [Related]
18. Circulating endothelial cells in patients with acute myeloid leukemia.
Wierzbowska A; Robak T; Krawczyńska A; Wrzesień-Kuś A; Pluta A; Cebula B; Smolewski P
Eur J Haematol; 2005 Dec; 75(6):492-7. PubMed ID: 16313261
[TBL] [Abstract][Full Text] [Related]
19. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D
Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458
[TBL] [Abstract][Full Text] [Related]
20. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
